Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-10-21
1996-05-07
McKane, Joseph K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514362, 514363, 514378, 514380, 546153, 546155, 546159, 546162, 546167, 546172, 548241, 548243, 548244, 548245, A61K 31435, C07D26106, C07D21502
Patent
active
055146910
ABSTRACT:
N-(4-halo-isoxazolyl)sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(4-halo-3-isoxazolyl)sulfonamides and N-(4-halo-5-isoxazolyl)benzenesulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
REFERENCES:
patent: 3300488 (1967-01-01), Onoue et al.
patent: 3660383 (1972-05-01), Sumimoto et al.
patent: 4997836 (1991-05-01), Sugihara et al.
patent: 5114918 (1992-05-01), Ishikawa et al.
patent: 5208243 (1993-05-01), Peglon et al.
patent: 5270313 (1993-12-01), Burri et al.
patent: 5378715 (1995-01-01), Stein et al.
patent: 5389620 (1995-02-01), Ishikawa et al.
patent: 5389633 (1995-02-01), Miyake et al.
patent: 5407941 (1995-04-01), Carceller et al.
patent: 5420123 (1995-05-01), Murugesan
patent: 5420129 (1995-05-01), Breu et al.
patent: 5420131 (1995-05-01), Carceller et al.
patent: 5420133 (1995-05-01), Dhanoa et al.
patent: 5420138 (1995-05-01), Corbier et al.
patent: 5420275 (1995-05-01), Masuya et al.
(CA): 112(19)178747t, 1989.
CA: 98(25)215517h, 1982.
CA: 94(23)192202c, 1980.
CA: 84(11)73173c, 1975.
CA: 83(23)191975t, 1975.
CA: 80(17)95868c, 1974.
CA: 77(17)113370d, 1972.
CA: 77(13)83384s, 1972.
CA: 73(23)120511w, 1967.
CA: 70(19)87635c, 1968.
CA: 70(1)4103d, 1968.
CA: 67(3)11468t, 1966.
CA: 67(5)21903v, 1965.
CA: 116(23)235529g, 1991.
CA: 116(5)4095m, 1991.
CA: 80(25)146111k, 1974.
CA: 66(19)85762k, 1967.
CA: 111(7)57717d, 1988.
CA: 110(15)135176x, 1987.
CA: 109(18)162247, 1988.
CA: 120(9)94890m, 1991.
CA: 119(25)262066x, 1993.
CA: 119(7)65021c, 1993.
CA: 117(25)245036d, 1992.
CA: 117(13)124085k, 1992.
CA: 117(3)19848p, 1992.
CA: 115(23)247397e, 1991.
CA: 114(17)156648a, 1991.
CA: 114(17)156647z, 1991.
CA: 114(11)95016u, 1990.
CA: 114(7)55340p, 1990.
CA: 114(3)17049t, 1990.
CA: 110(14)121203s, 1988.
CA: 108(23)197876t, 1988.
CA: 107(23)215074r, 1987.
CA: 107(13)108750m, 1987.
CA: 107(9)74639q, 1987.
CA: 105(13)107865z, 1986.
CA: 110(21)185301e, 1989.
CA: 107(23)215074r, 1987.
CA: 107(13)108750m, 1987.
CA: 107(9)74639q, 1987.
CA: 106(1)110t, 1985.
CA: 104(25)218557z, 1986.
CA: 102(21)182241j, 1985.
CA: 108(11)94444w, 1987.
CA: 108(9)68229k, 1987.
CA: 108(9)68228j, 1987.
CA: 107(13)108750m, 1987.
CA: 93(19)179284r, 1980.
CA: 78(1)77r, 1972.
CA: 76(15)85737n, 1971.
CA: 76(13)68021g, 1971.
CA: 75(1)5884z, 1970.
CA: 116(21)213114r, 1992.
CA: 11(9)74672c, 1989.
CA: 110(21)185301e, 1989.
CA: 109(3)16570r, 1988.
CA: 108(7)54535v, 1988.
CA: 107(23)215074r, 1987.
CA: 107(13)108750m, 1987.
CA: 107(9)74639q, 1987.
CA: 106(7)43380y, 1986.
CA: 106(1)110t, 1985.
CA: 105(13)107865z, 1986.
CA: 104(25)218557z, 1986.
CA: 103(19)153413g, 1985.
CA: 102(21)182241j, 1985.
CA: 102(17)147630p, 1985.
CA: 96(6)40928x, 1981.
CA: 82(17)110544f, 1974.
CA: 80(2)6932d, 1973.
CA: 73(23)120511w, 1970.
CA: 70(19)87639g, 1968.
CA: 70(1)4102c, 1968.
CA: 101(16)137107p, 1984.
CA: 87(1)631c, 1977.
CA: 76(11)56259c, 1971.
CA: 74(23)125679n, 1970.
CA: 74(17)87945m, 1970.
CA: 74(11)53764m, 1970.
CA: 73(23)117784g, 1969.
CA: 73(19)988851h, 1970.
CA: 72(19)100676e, 1970
CA: 70(15)68350q, 1968.
CA: 70(13)57821t, 1968.
CA: 68(21)94582v, 1967.
CA: 68(9)39615g, 1967.
CA: 67(7)32627j, 1966.
CA: 67(5)21903v, 1966.
CA: 66(15)65458n, 1967.
CA: 74(17)86290g, 1970.
CA: 72(19)100676e, 1970.
CA: 71(26)128748h, 1967.
CA: 70(9)37686z, 1968.
CA: 69(9)3611a, 1967.
CA: 69(3)10427h, 1967.
CA: 69(2)5219n, 1968.
CA: 66(15)65458n, 1967.
CA: 66(1)1504s, 1966.
CA: 120(13)158152g, 1993.
CA: 120(12)144339m, 1993.
CA: 120(12)144337j, 1993.
CA: 120(9)105206w, 1993.
Fujimoto, et al., "Isoxazole derivatives. II. Synthesis and structure of N-acylsufodiazoles and their homologs", Chemical Abstracts, vol. 65, No. 2, Jul. 18, 1966, Abstract No. 2241eq.
Stein, et al., "The Discovery of Sulfonamide Endothelin Antagonsits and the Development of the Orally Active ET.sub.A -Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide," J. Med. Chem. 37(3):329-331 (1994).
Doherty, "Endothelin: A new challenge, " J. Medicinal Chem., 35(9): 1493-1508 (1992).
Bolger et al., "Characterization of binding of the Ca++ channel antagonist .sup.3 H!nitrendipine, to guinea-pig ileal smooth muscle," J. of Pharmacology and Experimental Therapeutics, 225:291-309 (1983).
Williams et al., "Sarafotoxin S6c: An agonist which distinguishes between endothelin receptor subthpes," Biochem. and Biophys. Research Commun., 175(2):556-561 (1991).
Ihara et al., "An endothelin receptor (ET.sub.--) antagonist isolated from Streptomyces misakiensis,"Biochem, and Biophys. Research Commun., 178(1):132-137 (1991).
Spinella et al., "Design and synthesis of a specific endothelin 1 antagonist: Effects of pulmonary vasoconstriction," Proc. Natl. Acad. Sci. USA, 88p:7443-7446 (1991).
Saeki et al. "IAla.sup.1,3,11,16 !endothelin-1 analogs with ET.sub.8 agonistic activity," Biochem. and Biophys. Research Commun., 179(1):286-292 (1991).
Gu et al., The inhibitory effect of D-Arg.sup.1, D-Phe, D-Try.sup.7,9, Leu.sup.11 !substances P of endothelin-1 binding sites
Panek et al., "Endothelin and structurally related analogs distinguish between endothelin receptor subtypes," Biochem. and Biophys. Research Commun., 183(2):566-571 (1992).
Ihara et al., "Biological profiles of highly potent novel endothelin antagonists selective for the ET.sub.A receptor," Life Sciences, 50:247-255 (1991).
Hirata et al., "Receptor binding activity and cytosolic free calcium response by synthetic endothelin analogs in culture rat vascular smooth muscle cells," Biochem. and Biophys. Research Commun., 160:228-234 (1989).
Nakajima et al., "Synthesis of endothelin-1 analogues, endothelin-3, and sarafotoxin S6b: Structure-activity relationships," J. of Cardiovascular Pharm., 13(Suppl. 5):S8-S12 (1989).
Yanagisawa et al., "A novel potent vasoconstrictor peptide produced by vascular endothelial cells," Nature, 332:411-415 (1989).
Kashiwabara et al., "Putative precursors of endothelin have less vasoconstrictor activity in vitro but a potent pressor effect in vivo, FEBS Letters, 247(1): 73-76 (1989).
von Geldern et al., "A fluorogenic assay for endothelin-converting enzyme," Peptide Research, 4(1):32-35 (1991).
Inoue et al., "The human endothelin family: Three structually and pharmacologically distinct isopeptides predicted by three separate genes," Proc. Natl. Acad. Sci. USA, 86:2863-2867 (1989).
Saida et al., "A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family," J. Biol. Chem., 264(25):14613-14616 (1989).
Stewart et al., "Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of desease?" Annals of Internal Medicine, 114(6)464-469 (1991).
Brooks et al., "Effect of nifedipine on cyclosporine A-induced nephrotoxicity, unirary endothelin excretion and renal endothelin receptor number," Eur. J. of Pharmacology, 194:115-117 (1991).
Bolger et al., "Vascular reactivity, tissue levels, and binding sites for endothelin: A comparison in the spontaneously hypertensive and Wistar-Kyoto rats," Can. J. Physiol. Pharm., 69:406-413 (1990).
Simonson et al., "Endothelin-1 stimulates contraction of rate glomerular mesangial cells and potentiaties .sub.- -Adrenergic-mediated cyclic adenosine monophosophate accumulation," J. Clin. Invest., 85:790-797 (1990).
Takayanagi et al., "Presence of non-selective type of endothelin receptor on vascular endothelium and its likage to vasodilation," FEBS Letters, 282(1):103-106 (1991).
Nishikori et al., "Receptor binding affinity and biological activity of C-terminal elongated forms of endothelin-1," Neurochem. Int., 18(4):535-539 (1991).
Castiglione et al., "Alanine scan of endothelin," Peptides: Chemistry and Biology, Proc. Amer. Rept. Symp. (Twelfth), J. A. Smith and J. E. Rivier,
Balaji Vitukudi N.
Castillo Rosario S.
Chan Ming F.
Kois Adam
Raju Bore G.
ImmunoPharmaceutics, Inc.
McKane Joseph K.
Seidman Stephanie L.
LandOfFree
N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1227510